VRTX

Vertex Pharmaceuticals Incorporated

Price

$546.12

return (12m)

37.87%

p/e

31.75

p/bv

6.91

DIVIDEND YIELD

0.00%

VRTX price

Vertex Pharmaceuticals

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment VRTX

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

2.72%

3 months

23.29%

1 year

37.87%

2 years

16.69%

5 years

185.37%

10 years

482.96%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals VRTX

Valuation

P/E

31.75

Sector -3.73

Industry -3.73

P/BV

6.91

Sector 2.16

Industry 2.16

P/Revenue (PSR)

11.11

Sector 2.15

Industry 2.15

EV/EBITDA

99.63

Sector -221.18

Industry -221.18

EV/EBIT

104.07

Sector -47.52

Industry -47.52

P/EBITDA

26.56

Sector -21.48

Industry -21.48

P/EBIT

27.73

Sector -31.80

Industry -31.80

P/Total Assets

5.10

Sector 1.26

Industry 1.26

P/Net Current Assets

26.06

Sector -11.06

Industry -11.06

P/Working Capital

16.25

Sector -190.98

Industry -190.98

EPS

17.36

Sector -1.77

Industry -1.77

BVPS

79.81

Sector 2.05

Industry 2.05

Efficiency

Gross Margin

86.00%

Sector 41.11%

Industry 41.11%

EBITDA Margin

39.75%

Sector -17,824.00%

Industry -17,824.00%

EBIT Margin

38.05%

Sector -4,221,656.00%

Industry -4,221,656.00%

Operating Margin

37.95%

Sector -34.64%

Industry -34.64%

Net Profit Margins

35.00%

Sector -35.45%

Industry -35.45%

Asset Turnover

0.12

Sector 0.03

Industry 0.03

Profitability

ROE

21.76%

Sector -56.40%

Industry -56.40%

ROA

16.06%

Sector -59.80%

Industry -59.80%

ROIC

25.28%

Sector -2,338.86%

Industry -2,338.86%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

3.19

Sector 2.89

Industry 2.89

Net Debt / EBITDA

-5.93

Sector -14,697,933.03

Industry -14,697,933.03

Net Debt / EBIT

-6.19

Sector -8.34

Industry -8.34

Net Debt / Equity

-0.39

Sector -34,400.71

Industry -34,400.71

Gross Debt / Equity

0.00

Sector -0.85

Industry -0.85

Equity/Assets

0.74

Sector 0.46

Industry 0.46

Liabilities/Assets

0.26

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

10.69%

Sector -

Industry -

5Y Earnings CAGR

13.47%

Sector -

Industry -

Fundamentals VRTX

DRAG THE FRAME TO SEE MORE DATA

FAIR VALUE OF Vertex Pharmaceuticals ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$546.12

Fair Value

$176.56

Upside Return potential.

-67.67%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
VRTX Vertex Pharmaceuticals Incorporated	$546.12	37.87%	0.00%	31.75	6.91	21.76%	35.00%
JNJ Johnson & Johnson	$275.23	58.90%	1.90%	31.48	7.79	24.76%	21.48%
PFE Pfizer Inc.	$28.64	23.67%	6.01%	37.36	1.91	5.11%	6.86%
ABBV AbbVie Inc.	$256.46	24.50%	2.66%	72.11	-76.75	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.74	-12.60%	3.97%	11.43	6.07	53.11%	35.32%
MRK Merck & Co. Inc.	$150.67	85.99%	2.24%	116.76	8.81	7.55%	4.76%
AZN AstraZeneca PLC	$162.57	1.81%	1.98%	19.30	4.97	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$66.82	48.47%	3.75%	14.74	6.13	41.55%	18.85%
ZTS Zoetis Inc.	$75.81	-49.60%	2.76%	11.95	10.04	84.02%	27.77%
AMGN Amgen Inc.	$438.54	60.04%	2.25%	26.93	20.14	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$827.72	44.93%	0.44%	19.82	2.71	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$110.19	47.06%	0.00%	31.19	89.88	288.13%	24.86%
MCK McKesson Corporation	$917.36	33.47%	0.36%	20.52	-28.15	-137.16%	1.29%
CAH Cardinal Health Inc.	$247.18	67.38%	0.83%	37.62	-21.79	-57.93%	0.62%
ARGX argenx SE	$1,038.19	43.79%	0.00%	3.11	3.48	112.18%	44.41%
HRMY Harmony Biosciences Holdings Inc.	$42.15	12.31%	0.00%	13.47	2.44	18.14%	18.88%
BIIB Biogen Inc.	$220.83	56.98%	0.00%	39.04	1.73	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

VRTX Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated

Average Investor10 user rating

5.0 (25 people)

United States

37 years

Founded: 1989

1991

Time since IPO - 35 years

3.400

Employees

Vertex Pharmaceuticals Incorporated (United States) is listed on the Nasdaq and has a market capitalization of $139.89 billion, with shareholders equity totaling $20.25 billion.

The company employs approximately 3.400 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Vertex Pharmaceuticals Incorporated reported $12.59 billion in revenue, generating net income of $4.41 billion.

Key financial metrics include a P/E ratio of 31.75, a price-to-book (P/B) ratio of 6.91, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker VRTX.

Market cap

$139.89 billion

Net worth

$20.25 billion

$20,247,900,000.00

Assets

$27.42 billion

$27,423,300,000.00

Total Shares Outstanding

253.70 million

253,700,000

Average Daily Trading Volume

$1.48 million

$1,482,426.18

Sector

Health Care

Industry

Biotechnology

VRTX

revenue by Business Segment Vertex Pharmaceuticals

Revenue by Region Vertex Pharmaceuticals

VRTX revenue and profits

Financial Results VRTX

DRAG THE FRAME TO SEE MORE DATA

VRTX cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$917.36 34,00% (12M)

P/E

20.52

0.36%

ROE

-137.16%

P/BV

-28.15

CAH - Cardinal Health

$247.18 67,38% (12M)

P/E

37.62

0.83%

ROE

-57.93%

P/BV

-21.79

JNJ - Johnson & Johnson

$275.23 58,90% (12M)

P/E

31.48

1.90%

ROE

24.76%

P/BV

7.79

ABBV - AbbVie

$256.46 24,50% (12M)

P/E

72.11

2.66%

ROE

-106.44%

P/BV

-76.75

MRK - Merck & Co.

$150.67 83,76% (12M)

P/E

116.76

2.24%

ROE

7.55%

P/BV

8.81

AZN - AstraZeneca

$162.57 0,71% (12M)

P/E

19.30

1.98%

ROE

25.77%

P/BV

4.97

PFE - Pfizer

$28.64 23,22% (12M)

P/E

37.36

6.01%

ROE

5.11%

P/BV

1.91

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$917.36 34,00% (12 M)

P/L

20.52

0.36%

ROE

-137.16%

P/VP

-28.15

CAH - Cardinal Health

$247.18 67,38% (12 M)

P/L

37.62

0.83%

ROE

-57.93%

P/VP

-21.79

JNJ - Johnson & Johnson

$275.23 58,90% (12 M)

P/L

31.48

1.90%

ROE

24.76%

P/VP

7.79

ABBV - AbbVie

$256.46 24,50% (12 M)

P/L

72.11

2.66%

ROE

-106.44%

P/VP

-76.75

MRK - Merck & Co.

$150.67 83,76% (12 M)

P/L

116.76

2.24%

ROE

7.55%

P/VP

8.81

AZN - AstraZeneca

$162.57 0,71% (12 M)

P/L

19.30

1.98%

ROE

25.77%

P/VP

4.97

PFE - Pfizer

$28.64 23,22% (12 M)

P/L

37.36

6.01%

ROE

5.11%

P/VP

1.91

Frequently Asked Questions

What is the price of Vertex Pharmaceuticals (VRTX) today?

A cotação de Vertex Pharmaceuticals (VRTX) hoje está em US$ 546.12, com uma variação de 37.87% em relação ao último ano. A cotação de Vertex Pharmaceuticals (VRTX) iniciou o ano negociando na casa dos US$ 453.36 e hoje está em US$ 546.12. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Vertex Pharmaceuticals (VRTX) e dados de ações do Ibovespa e mercados internacionais.

Quando Vertex Pharmaceuticals (VRTX) paga dividendos?

Vertex Pharmaceuticals (VRTX) não distribuiu dividendos no último ano.

Is Vertex Pharmaceuticals (VRTX) a good investment?

Atualmente, Vertex Pharmaceuticals (VRTX) está cotada a US$ 546.12, com um P/L de 31.75, representando um desvio de -1,594% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 37.87 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 37.87%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Vertex Pharmaceuticals (VRTX) stock?

Investir em ações de Vertex Pharmaceuticals (VRTX) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Vertex Pharmaceuticals (VRTX) yield today?

A rentabilidade de Vertex Pharmaceuticals (VRTX) foi de 2.72% no último mês, 37.87% no último ano e 185.37% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Vertex Pharmaceuticals (VRTX) hoje, o investimento total seria de US$ 54,612.00, com base na cotação atual de US$ 546.12.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 75,293.56
Em 5 anos: US$ 155,846.26
Em 10 anos: US$ 318,366.12

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

VRTX

Vertex Pharmaceuticals Incorporated

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment VRTX

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING VRTX WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated

United States

37 years

1991

3.400

PROFIT X PRICE VRTX

Financial Results VRTX

VRTX cash flow

Asset, Revenue and Profit Growth - VRTX

VRTX balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions